DEF 14A: Vicarious Surgical Seeks OK for 2.3M Class A Share Warrants

Vicarious Surgical Inc. is holding a special meeting on January 9, 2026, to seek stockholder approval for the exercise of common warrants to purchase up to 2,300,000 shares of Class A common stock.

Summary

• A Special Meeting of Stockholders will be held on Friday, January 9, 2026, at 4:30 p.m., Eastern Time, at the company's offices in Waltham, Massachusetts.
• The primary purpose of the meeting is to approve the exercise of Common Warrants, issued on October 7, 2025, to purchase up to an aggregate of 2,300,000 shares of Class A common stock.
• This approval is required under applicable rules and regulations of the New York Stock Exchange (NYSE) because the transaction involves more than 20% of the company's outstanding common stock.
• The Common Warrants have an initial exercise price of $5.10 per share and will become exercisable upon stockholder approval.
• The company previously conducted a registered direct offering and a concurrent private placement on October 7, 2025, which included these warrants and yielded gross proceeds of approximately $5.9 million.
• As of September 30, 2025, the company had approximately $3.2 million in cash and cash equivalents and $10.3 million in short-term investments, necessitating the capital raise for general corporate purposes.
• If all Common Warrants are exercised for cash at their initial exercise price, the company could realize up to an additional approximately $11.7 million in gross proceeds.
• The Board of Directors unanimously recommends that stockholders vote 'FOR' the approval of this proposal.

Sentiment

Score: 6

Explanation: The filing outlines a necessary capital raise to support operations, which is positive for liquidity. However, it also highlights potential future dilution for existing shareholders and the ongoing need for funds suggests operational cash requirements. The board's recommendation for approval indicates a strategic necessity.

Positives

• Potential to raise up to an additional $11.7 million in gross proceeds if all 2,300,000 common warrants are exercised for cash at the initial exercise price of $5.10 per share, providing crucial funding for general corporate purposes.
• The initial offerings in October 2025, which included these warrants, already yielded approximately $5.9 million in gross proceeds, addressing immediate funding requirements.
• The Board of Directors determined that the offerings were necessary given the company's cash and funding requirements as of September 30, 2025, and found the terms to be the most favorable among considered alternatives.

Negatives

• Existing stockholders will experience dilution in their ownership interests upon the issuance of up to 2,300,000 additional shares of Class A common stock from warrant exercise.
• The sale of these additional shares into the public market could materially and adversely affect the market price of Class A common stock.
• Failure to approve the proposal means the company will not receive the potential $11.7 million in proceeds, which could adversely impact its ability to fund operations.
• If the proposal is not approved, the company will incur substantial additional costs and expenses by needing to hold another stockholder meeting every 120 days until approval is obtained or the warrants are no longer outstanding.

Risks

• Dilution of existing stockholder ownership interests upon the issuance of shares from warrant exercise.
• Potential adverse impact on the market price of Class A common stock due to the sale of additional shares into the public market.
• Adverse impact on the company's ability to fund operations if the warrants cannot be exercised and the potential $11.7 million in proceeds are not received.
• Incurrence of substantial additional costs and expenses if repeated stockholder meetings are required due to non-approval of the warrant exercise.

Future Outlook

The company anticipates receiving up to an additional $11.7 million in funding for general corporate purposes upon the exercise of the Common Warrants, contingent on stockholder approval. Failure to secure this approval would prevent the realization of these funds and necessitate further, costly stockholder meetings every 120 days until approval is obtained or the warrants are no longer outstanding.

Management Comments

• "Our board of directors recommends the approval of this proposal."
• "We believe that the Offerings, which yielded gross proceeds of approximately $5.9 million, were necessary in light of our cash and funding requirements at the time."
• "Our Board of Directors considered numerous other alternatives to the transactions, none of which proved to be feasible or, in the opinion of our Board of Directors, would have resulted in aggregate terms equivalent to, or more favorable than, the terms obtained in the Offerings."

Industry Context

This announcement primarily concerns Vicarious Surgical's internal capital structure and financing needs, rather than broader industry trends. The need for additional capital suggests the company is in a growth or development phase requiring significant investment, common for innovative medical device companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential dilution of ownership interests upon warrant exercise; potential adverse impact on stock price from increased shares in the market. Voting on a significant capital structure change.
• Company: Access to up to $11.7 million in additional capital for general corporate purposes if warrants are exercised, improving liquidity and funding operations. Incurs costs for proxy solicitation and potential future meetings if approval is not granted.
• Warrant Holders (Purchaser): Ability to exercise warrants and acquire Class A common stock, contingent on stockholder approval, providing a mechanism for their investment to convert to equity.

Next Steps

• Hold a Special Meeting of Stockholders on January 9, 2026, to vote on the warrant exercise proposal.
• Publish preliminary or final voting results in a Current Report on Form 8-K within four business days of the special meeting.
• If final results are unavailable at the time of the initial Form 8-K filing, file an amended report on Form 8-K to disclose the final voting results within four business days after they are known.
• If Proposal No. 1 is not approved, the company is obligated to call additional stockholder meetings every 120 days thereafter until approval is obtained or the Common Warrants are no longer outstanding.

Key Dates

Recommendation

The company is undertaking a necessary capital raise to fund operations, which is a positive for its short-term viability. However, the significant potential dilution from the warrant exercise and the ongoing need for capital suggest underlying challenges. Investors should hold to observe the company's progress in utilizing these funds and its operational performance before making further investment decisions. The approval of the warrants is a procedural step for a pre-arranged financing, not a new strategic initiative.

Keywords

Vicarious Surgical, RBOT, Warrants, Stockholder Approval, Capital Raise, Class A Common Stock, NYSE, Proxy Statement, Dilution, Special Meeting, Financial Health, Medical Devices